Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 9/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30018553 | 1.00 | EGFR (0.45) | EGFRFGFR3INSRIGF1RALK | |
| SCHEMBL23154031 | 0.95 | EGFR (0.41) | EGFRFGFR3INSRIGF1RALK | |
| SCHEMBL22520158 | 0.90 | FGFR3 (0.42) | EGFRFGFR3ACVR1KCNH2FGFR1 | |
| SCHEMBL10207156 | 0.90 | PDCD1 (0.41) | — | |
| SCHEMBL23759586 | 0.90 | FGFR3 (0.45) | EGFRFGFR3INSRIGF1RALK | |
| SCHEMBL23759617 | 0.89 | HTR1A (0.44) | — | |
| SCHEMBL3122615 | 0.88 | CCR4 (0.42) | — | |
| SCHEMBL23154131 | 0.87 | ALDH1A1 (0.45) | — | |
| SCHEMBL25011531 | 0.86 | GAA (0.42) | EGFRFGFR3INSRIGF1RALK | |
| SCHEMBL25011508 | 0.86 | GAA (0.43) | EGFRFGFR3ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297194-B2 | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof | Bridge Biotherapeutics, Inc. (KR) | 2025-05-13 | — | — | US | disclosed |
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | INNOVATION INSTITUTE FOR ARTIFICIAL INTELLIGENCE IN MEDICINE OF ZHEJIANG UNIVERSITY (CN) | 2025-03-27 | — | — | US | disclosed |
| US-20240360102-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVE, A PREPARATION METHOD THEREFOR, AND A PHARMACEUTICAL APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-10-31 | — | — | US | disclosed |
| CN-118772111-A | Substituted aminopyrimidine compound, pharmaceutical composition and application thereof | 江南大学 | 2024-10-15 | — | — | CN | disclosed |
| EP-4393930-A1 | CRYSTAL FORMS, PREPARATION METHOD AND APPLICATION OF ARYL PHOSPHINE OXIDE COMPOUND | Chengdu Di'Ao Jiuhong Pharmaceutical Factory (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-4382520-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVE, A PREPARATION METHOD THEREFOR, AND A PHARMACEUTICAL APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-20240051940-A1 | SULFONAMIDES WITH EGFR INHIBITION ACTIVITIES AND THEIR USE THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-02-15 | — | — | US | disclosed |
| EP-4313969-A1 | N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF | Bridge Biotherapeutics, Inc. (KR) | 2024-02-07 | — | — | EP | disclosed |
| CN-116981662-A | Pyrimidine-4, 6-diamine derivative, preparation method and pharmaceutical application thereof | 上海和誉生物医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-112513029-B | Nitrogen-containing aryl phosphorus oxide derivative, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-3656769-A1 | ARYL-PHOSPHORUS-OXYGEN COMPOUND AS EGFR KINASE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-05-27 | — | — | EP | disclosed |
| EP-2601186-A2 | 4-(1H-INDOL-3-YL)-PYRIMIDINES AS ALK INHIBITORS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ALK, BRAF, ABL1 | EGFR 40/4885FGFR3 87/4885INSR 860/4885 |
| US-12297194-B2 | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof | EGFR, ERBB2, ERBB4 | EGFR 1/4885FGFR3 48/4885INSR 1593/4885 |
| US-20240051940-A1 | SULFONAMIDES WITH EGFR INHIBITION ACTIVITIES AND THEIR USE THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885FGFR3 27/4885INSR 1065/4885 |
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | EGFR, ERBB2, ERBB3 | EGFR 1/4885FGFR3 9/4885INSR 75/4885 |
| US-20240360102-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVE, A PREPARATION METHOD THEREFOR, AND A PHARMACEUTICAL APPLICATION THEREOF | WEE1, WEE2, EGFR | EGFR 3/4885FGFR3 75/4885INSR 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.